ALGM vs G

ALGM's deterministic health scores signal significant financial distress: the Piotroski F-Score of 2/9 indicates weak operational and financial health, while the absence of an Altman Z-Score raises concerns about bankruptcy risk. Despite strong revenue growth (28.9% YoY) and positive earnings momentum (114.3% YoY EPS growth), the company reports negative profit margins (-1.57%) and ROE (-1.36%), undermining profitability sustainability. Insider selling totaling $1.65M over six months and a bearish technical trend further erode confidence. The stock trades at a premium valuation (Forward P/E: 33.05, Price/Sales: 6.87) relative to its weak fundamentals, suggesting overvaluation.

Genpact presents a classic value-trap profile, characterized by a stable Piotroski F-Score of 4/9 and a current price ($34.32) trading very close to its Graham Number ($32.47). While the company maintains a strong ROE of 22.37% and a very attractive forward P/E of 7.73, these fundamentals are offset by a disastrous technical trend (0/100) and bearish insider activity. The core business faces significant existential risks from generative AI, which the 10-K explicitly notes could replace existing services and reduce demand. Consequently, the deep valuation discount is likely a reflection of the market pricing in structural industry disruption.